JPMorgan Chase & Co. set a €120.00 ($139.53) target price on MorphoSys (ETR:MOR) in a research report released on Friday, Borsen Zeitung reports. The firm currently has a buy rating on the stock.

A number of other equities analysts have also commented on the stock. Berenberg Bank set a €108.00 ($125.58) price objective on shares of MorphoSys and gave the stock a buy rating in a report on Tuesday, April 2nd. Goldman Sachs Group set a €114.00 ($132.56) price objective on shares of MorphoSys and gave the stock a neutral rating in a report on Friday, January 18th. Royal Bank of Canada set a €65.00 ($75.58) price objective on shares of MorphoSys and gave the stock a sell rating in a report on Monday, February 4th. Deutsche Bank set a €125.00 ($145.35) price objective on shares of MorphoSys and gave the stock a buy rating in a report on Friday, April 26th. Finally, Independent Research set a €96.00 ($111.63) target price on shares of MorphoSys and gave the stock a neutral rating in a research report on Thursday, March 14th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of Hold and a consensus target price of €100.78 ($117.18).

Shares of MOR stock opened at €93.30 ($108.49) on Friday. MorphoSys has a 12 month low of €76.45 ($88.90) and a 12 month high of €124.90 ($145.23). The company has a current ratio of 7.75, a quick ratio of 7.53 and a debt-to-equity ratio of 8.65. The firm has a market capitalization of $2.95 billion and a price-to-earnings ratio of -50.22.

MorphoSys Company Profile

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.

Featured Story: Is the Dow Jones Industrial Average (DJIA) still relevant?

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.